ProShare Advisors
NYMX

ProShare Advisors’s Nymox Pharmaceutical Corp NYMX Stock Holding History

ProShare Advisors’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,299
Closed -$25K – 2423
2021
Q1 		$25K Buy
+11,299
New +$29.8K ﹤0.01% 2255

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TEE
Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.7B AUM 31.52% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

ProShare Advisors's NYMX Position: Q2 2021 in Review

ProShare Advisors sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2021, closing a stake of 11,299 shares — an estimated $25K sold.

ProShare Advisors first reported a position in NYMX in Q1 2021 and held it in 1 quarter. The position peaked at $25K in Q1 2021. 51 funds tracked by Wall St. Rank hold NYMX as of Q2 2021.

  • ProShare Advisors reported no remaining Nymox Pharmaceutical Corp position as of Q2 2021 after selling out during the quarter.
  • ProShare Advisors sold 11,299 Nymox Pharmaceutical Corp shares in Q2 2021, an estimated $25K.
  • ProShare Advisors first reported a position in Nymox Pharmaceutical Corp in Q1 2021 and held it in 1 quarter.
  • ProShare Advisors's Nymox Pharmaceutical Corp position peaked at $25K in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.